Study findings suggest the benefits of continuing ACEi or ARB therapy outweigh the risks in CKD patients with an eGFR less than 30 mL/min/1.73 m2.
Hyperkalemia, hypomagnesemia, and hyperparathyroidism commonly persist after kidney transplant surgery.
In a study, sodium zirconium cyclosilicatesimilarly maintained normokalemia in nondialysis CKD patients with an eGFR above and below a threshold of 30 mL/min/1.73 m2.
Polypharmacy and medication errors can expose elderly patients with chronic kidney disease to an increased risk of hyperkalemia and other problems, investigators reported.
In a small study, use of the potassium binder sodium zirconium cyclosilicate in transplant recipient did not appear to compromise immunosuppression with tacrolimus.
Findings from a real-world study of veterans revealed persistent use of patiromer in many patients over a 6-month period following initiation of the drug.
Content sponsored by AstraZeneca An estimated 37 million Americans in the United States (US) live with chronic kidney disease (CKD) and its complications. That’s roughly 15 percent of the adult population.1 Despite the high unmet need, innovation has lagged in comparison to other disease areas. It’s time for that dynamic to change. Health care providers…
In a study of hospitalized patients, hypokalemia and hyperkalemia at admission were associated with an increased 1-year mortality risk.
Sodium zirconium cyclosilicate produced dose-dependent reductions in serum potassium in an international cohort of hyperkalemic outpatients.
Failure to correct dyskalemia within 2 days increased 28-day mortality risk.